問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
許舒嵐
下載
2025-03-01 - 2028-03-31
Condition/Disease
Test Drug
Participate Sites9Sites
Recruiting9Sites
2019-03-06 - 2022-02-28
Recruiting7Sites
Terminated1Sites
2021-03-01 - 2023-07-30
Participate Sites7Sites
2022-08-01 - 2027-12-31
Participate Sites10Sites
Recruiting10Sites
2020-05-01 - 2024-04-15
2020-01-06 - 2031-06-18
Participate Sites14Sites
Recruiting14Sites
2024-01-01 - 2030-12-31
Participate Sites17Sites
Recruiting17Sites
2025-04-01 - 2032-12-31
Participate Sites18Sites
Recruiting18Sites
2015-12-10 - 2019-12-31
NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES
(1)Avastin; (2) Erlotinib
Participate Sites3Sites
Recruiting3Sites
2019-04-01 - 2022-12-31
non-squamous non-small cell lung cancer
Durvalumab、Tremelimumab
Participate Sites8Sites
Recruiting8Sites
Division of General Internal Medicine
全部
